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ABSTRACT OF THE DISSERTATION 
Electrophysiology of the Inner Retina in Health and Disease: 
EAAT5 in the Rod Bipolar Cell and Oscillatory Potentials in Diabetes 
by 
Gregory W. Bligard 
Doctor of Philosophy in Biology and Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, 2020 
Professor Peter D. Lukasiewicz, Chair 
The inner retina is a highly tractable location for the study of neural networks in the central 
nervous system and improving our understanding of the inner retina is important for the 
treatment of a number of ophthalmic diseases. This dissertation aims to improve understanding 
of the inner retina in two parts: first, a basic neuroscientific project concerning normal neuronal 
processing in the inner retina at a cellular level, and second, a translational ophthalmologic 
project regarding the development in the inner retina of a common disease. 
In mammals, modulation of the amplitude of dim visual signals primarily occurs at axon 
terminals of rod bipolar cells. While such effects are largely mediated by conventional inhibitory 
neurotransmitter receptors, excitatory amino acid transporter 5 (EAAT5) also contributes a 
significant unconventional inhibitory activity. EAATs clear glutamate from the synapse, but they 
also have an intrinsic glutamate-gated chloride conductance. EAAT5 in particular has very little 
glutamate reuptake activity, and primarily acts as an inhibitory glutamate-gated chloride channel. 
In my primary project I demonstrate the relative contribution of EAAT5-mediated inhibition 
onto rod bipolar cells in response to physiologically relevant stimuli in retinal slice explants. In 
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this setting, I also compare the roles of autoinhibition, in which excitation of the cell leads to 
inhibition onto itself, and alloinhibition, which is driven by other bipolar cells. Contrary to prior 
reports, I found that EAAT-mediated inhibition can be elicited by dim light stimuli. I also found 
that while conventional inhibitors mediate nearly all alloinhibition onto rod bipolar cells, EAAT5 
is the primary mediator of rod bipolar autoinhibition. Finally, in silico modeling demonstrates 
that EAAT5-mediated autoinhibition may have a substantial impact on postsynaptic excitation of 
the downstream AII amacrine cell. My combined results suggest that EAAT5 autoinhibition in 
rod bipolar cells modulates the rod signaling pathway, possibly tuned to prevent long-term 
changes in baseline depolarization while still allowing single-photon signals to pass in the dark 
and transient signals to pass in the twilight. 
Obesity predisposes humans to type 2 diabetes, which may result in diabetic retinopathy, 
commonly understood to be fundamentally a vascular pathology. In my secondary project I seek 
to characterize the course of electroretinographic dysfunction in a high-fat diet–induced model of 
diabetes in mice. Mice weaned to chow or to a high-fat diet were tested for electroretinographic 
dysfunction at 3, 6 and 12 months of age. There is no evidence of microvascular disease in these 
mice until 12 months. However, at as early as 6 months, high fat–fed mice demonstrated 
increased latencies and reduced amplitudes of oscillatory potentials compared with controls. 
These electroretinographic abnormalities were correlated with glucose intolerance. The results 
suggest that retinal disease in the diabetic milieu may progress through neuro-retinal stages long 
before the development of vascular lesions representing the classic hallmark of diabetic 
retinopathy, establishing a model for assessing novel interventions to treat eye disease. 
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Chapter 1: Background and Introduction  
1.1 The Neural Circuitry of the Inner Retina 
The retina has long served as an experimentally tractable location for the study of the central 
nervous system, due in part to its physical accessibility, its relatively simple circuitry compared 
to the brain, and its precise, layered organization (Figure 1.1) [1]–[3]. Nevertheless, the 
vertebrate retina is still a complex neural network, and significant neuronal processing and 
filtering of visual information takes place in the retina itself before any visual signal even 
reaches the optic nerve [4]–[12]. 
 
Figure 1.1: The retina is a well-organized, laminar structure composed of five distinct classes of neurons. 
(Figure from [1].) Photoreceptors (PR) are hyperpolarized by light and synapse onto bipolar cells (BC) and 
horizontal cells (HC) in the outer plexiform layer (OPL). Bipolar cells then synapse onto ganglion cells (GC) and 
amacrine cells (AC) in the inner plexiform layer (IPL). 
 
Visual signaling begins with rod and cone photoreceptors, which continuously depolarize in 
darkness and release glutamate [13], [14]. Following the absorption of a photon, photoreceptor 
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opsins, acting via a G-protein-coupled receptor (GPCR) signal cascade, can close membrane 
channels, hyperpolarize the cell, and decrease glutamate release [15]–[17]. Photoreceptors 
transmit this information in parallel onto bipolar cells at synapses in the outer plexiform layer 
(OPL) [13]. Cone bipolar cells come in a number of varieties [18], but two main classes: in 
response to glutamate, OFF cone bipolar cells depolarize via ionotropic AMPA or kainate 
receptors [19], whereas ON cone bipolar cells hyperpolarize via sign-inverting metabotropic 
mGluR6 receptors [20]. Visual information passes from cone bipolar cells to ganglion cells via 
glutamatergic neurotransmission in the inner plexiform layer (IPL) [21]–[23], and from there, 
ganglion cell axons form the optic nerve, which passes visual information to the brain [24], [25]. 
Meanwhile, rods only synapse onto a single type of rod bipolar cell, which also receives its input 
via the mGluR6 metabotropic receptor [26]. Rod bipolar cells, in turn, synapse in the IPL onto 
AII amacrine cells [27]–[30]. Rod and cone pathways converge where AII amacrines make gap 
junctions with ON cone bipolar cells and glycine-mediated inhibitory synapses onto OFF cone 
bipolar cells (Figure 1.2) [31]–[33]. Additional lateral communication and signal modulation 
between these pathways takes place through horizontal cells at the OPL and many forms of 




Figure 1.2: Rod pathways in the mouse retina utilize cone circuitry. 
(Figure from [33].) Rods synapse onto a single class of rod bipolar cell, which synapses onto the AII amacrine cell.  
The AII generates parallel streams of ON and OFF by forming excitatory electrical synapses with ON cone bipolar 
cells and inhibitory glycine synapses with OFF cone bipolar cells, respectively. 
 
Astoundingly, this neural network is capable of interpreting visual stimuli presented over more 
than 12 orders of magnitude of ambient luminance [41], [42], a feat that is only possible with 
sophisticated neuronal gain control systems. Such flexibility is achieved in part by a transition 
from rod-mediated vision in darkness to cone-mediated vision in bright light [43], [44], but rod 
vision alone still operates over a luminous range that far exceeds the dynamic range that 
ganglion cells would be capable of encoding without mechanisms for signal gain control. Gain 
modulation is attributable both to adaptation within photoreceptors themselves as well as to 
adaptation of the neural network downstream of the photoreceptors [45]–[50]. Our understanding 
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of primary photoreceptor adaptation has become quite sophisticated, but the mechanisms behind 
retinal network adaptation are less well understood [51]. 
1.2 Excitatory Amino Acid Transporters 
Ion channel gating and neurotransmitter transport are mechanistically distinct processes that are 
typically performed by separate proteins. Ion channels are pores that allow the diffusion of ions 
along preexisting electrochemical gradients, while neurotransmitter transporters actively pump a 
substrate against its electrochemical gradient [52]. There are, however, a few novel 
neurotransmitter transporters that can also act as ion channels, including known transporters for 
dopamine, GABA, glutamate, norepinephrine, proline, and serotonin [53]–[61]. 
The excitatory amino acid transporters (EAATs) are one such family of neurotransmitter 
transport proteins. EAATs are members of the solute carrier family 1 (SLC1), which also 
includes two neutral amino-acid transporters, ASCT1 and ASCT2 [62], and are distinct from 
vesicular glutamate transporters. The EAAT family is best known for those members that act to 
terminate signaling in the CNS by removing released glutamate from synapses following 
neurotransmission. However, in certain members of the EAAT family, glutamate binding can 
instead open a chloride conductance through the transporter that suppresses synaptic activity, 
although its role in CNS signaling is poorly understood [63], [64]. 
Five mammalian EAATs have been discovered and are designated EAAT1 through EAAT5 
[64]–[66]. EAAT1, also known as SLC1A3 and GLAST1 (glutamate aspartate transporter 1) 
[67], is present in glial cells throughout the central nervous system and at high levels in 
Bergmann glia of the cerebellum. EAAT2, also known as SLC1A2 and GLT1 (glutamate 
transporter 1) [68], is almost exclusively glial, and is widespread and highly abundant throughout 
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the central nervous system. EAAT3, also known as SLC1A1 and EAAC1 (excitatory amino acid 
carrier 1) [69], is present in neurons throughout the CNS. EAAT4 (SLC1A6) is found in 
cerebellar Purkinje cells and in the forebrain [62], [70]–[72]. EAAT5 (SLC1A7) is localized to 
rod photoreceptors and rod bipolar cells in the retina [65], [73]. 
 
Figure 1.3: EAATs are both glutamate transporters and chloride channels. 
(Figure from [74].) A schematic diagram of an EAAT is shown. Glutamate is co-transported with three Na+ and one 
H+, along with the counter-transport of one K+. Glutamate and Na+ also activate a stoichiometrically uncoupled 
chloride conductance. 
 
The two functions of these proteins are not thermodynamically coupled. The rate of glutamate 
uptake is independent of chloride concentration, instead dependent on the cotransport of three 
sodium ions and one proton and the counter-transport of one potassium ion (Figure 1.3) [75]. 
Meanwhile the transporter’s chloride conductance is dependent on glutamate and sodium binding 
to the transporter, as well as membrane potential, but is thermodynamically independent of the 
rate or direction of glutamate transport (27-31) [76]–[81]. In addition, the balance between these 
two functions varies enormously between individual members of the EAAT family [82], [83]. 
EAAT1, EAAT2, and EAAT3 have little chloride conductance and play an important role in 
glutamate reuptake in the cells that express them [84], [85]. EAAT4 and EAAT5 have little 
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glutamate uptake activity, but instead play a novel role as a presynaptic inhibitory signaling 
mechanism in the cerebellum and retina, respectively [64], [86]. 
1.3 Electroretinography in Diabetic Retinopathy 
Diabetic retinopathy is an end-organ complication of diabetes mellitus and is a leading cause of 
blindness worldwide [87], [88]. It can take many years for a diabetic patient to develop 
symptoms of retinopathy, but patients can progress quite rapidly to blindness once symptoms 
appear [89]. In many ways current treatments are inadequate, and there is a critical need for a 
better understanding of the basic pathogenic mechanisms of this disease. 
The traditional understanding of diabetic retinopathy is that the metabolic defects of diabetes 
cause microvascular damage, inflammation, and loss of endothelial integrity in the retina. These, 
in turn, lead to grossly detectable changes such as microaneurysms, hemorrhages, macular 
edema, and vascular proliferation which all finally lead to neuronal damage in the inner retina 
and loss of vision. Thus, diabetic retinopathy is treated clinically with drugs and procedures 
aimed at reducing vascular leakage, proliferation, and edema. However, deficits in the oscillatory 
potential (OP) component of the electroretinogram (ERG) have been observed by a number of 
researchers in the retinas of patients prior to visible microvascular defects [90]–[93]. In fact, 
patients with diabetes but without funduscopic retinopathy were found with decreased OP 
amplitudes as early as 1962 [94]. Collectively, these studies suggest that functional changes may 
actually occur before vascular pathology. 
In the clinic, however, diabetic patients are still typically first seen and treated when they present 
with signs and symptoms attributable to retinal vascular pathology; electrophysiological visual 
testing is not regularly used to assess diabetic patients [95], [96]. Thus, a better understanding of 
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the neuronal deficits in the early-stage diabetic retina is ripe for clinical benefit; the identification 
of early functional changes might actually allow the prevention of later vascular pathologies 
before they even occur. 
1.4 Objectives of the Dissertation  
This thesis is intended to improve our understanding of the neural circuitry of the inner retina as 
a project in two independent parts. In the first and larger part, presented in Chapter 2, I have 
focused on a basic scientific question relating to retinal network signal modulation. Recently, 
evidence has arisen that an amino acid transporter, EAAT5, plays a substantial role in this 
inhibitory process. In Chapter 2, I present the results of experiments designed to expand our 
understanding of the novel role of this protein in inner retinal visual processing. Specifically, I 
begin by correcting a previously-published theory regarding the circumstances under which 
EAAT5 inhibition is actually active. I then examine whether EAAT5 primarily mediates 
autoinhibition or alloinhibition in rod bipolar cells, a question for which evidence supporting 
both possibilities had previously existed. Finally, I demonstrate the functional significance of 
EAAT5-mediated inhibition on visual processing. 
Revealing the function and mechanisms behind EAAT5-driven inhibition in retinal circuitry will 
not only fill the gaps in our understanding of visual processing but will also undoubtedly 
improve our understanding of neural circuit modulation in general, including a better 
understanding of the many roles that EAAT-mediated inhibition may play in other parts of the 
CNS. In addition, a better understanding of retinal circuitry is needed to elucidate the 
mechanisms underlying common eye diseases like macular degeneration, retinitis pigmentosa, 
congenital blindness, and diabetic retinopathy. In the second part of this dissertation, presented in 
Chapter 3, I shift focus from basic science to such a disease, concentrating in particular on the 
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neuronal effects of the early stages of diabetic retinopathy on the inner retina. Specifically, I 
present an analysis of electroretinograms (ERGs) recorded from high-fat diet (HFD) and control 
mice over 12 months. In so doing, I characterize the ERG changes that take place as diabetic 
retinopathy develops and demonstrate that despite the traditional understanding of diabetic 
retinopathy, electrophysiological deficits actually precede structural lesions in these mice. 
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Chapter 2: The Glutamate Transporter 
EAAT5 Mediates Rod Bipolar Cell 
Autoinhibition 
2.1 Background 
The retina is capable of responding to visual stimuli over more than 12 orders of brightness 
magnitude [41], [42], necessitating substantial gain modulation of neural signals to avoid 
response saturation and maintain sensitivity. In the rod pathway, gain modulation occurs 
primarily at the synapse between the rod bipolar and the AII amacrine cell [97]. It has long been 
understood that, in response to presentation of light stimuli, a variety of amacrine cell 
populations release GABA and glycine onto rod bipolar cell axon terminals, which activate 
GABAA, GABAC, and glycine receptors, evoking an inhibitory chloride conductance [98]–[106]. 
These conventional inhibitors mediate both autoinhibition, in which excitation of the cell leads to 
feedback inhibition onto itself, and alloinhibition, in which inhibition is driven by other bipolar 
cells and occurs independently of the activity of the cell of interest. Specifically, conventional 
autoinhibition of the rod bipolar cell is mediated via the A17 amacrine cell reciprocal synapse 
while conventional alloinhibition is mediated via various lateral amacrine cell pathways (Figure 




Figure 2.1: Conventional inhibition is mediated by a variety of sources. 
Rod bipolar cells receive presynaptic GABA-mediated autoinhibition from A17 amacrine cells and additional 
presynaptic alloinhibition from other GABAergic and glycinergic amacrine cells.                             
 
However, in addition to conventional inhibitors, rod bipolar cells are also subject to a presynaptic 
inhibition mediated by excitatory amino acid transporter 5 (EAAT5) [65]. Transporters in the 
EAAT family are thusly named for their role in removing glutamate from synapses following 
neurotransmission. Glutamate binding to EAATs can also open a chloride conductance through 
the transporter that suppresses synaptic activity [63], [64]. These two functions are not 
stoichiometrically coupled; the rate of glutamate uptake is independent of chloride concentration, 
while the transporter’s chloride conductance is dependent on glutamate, sodium, and membrane 
potential [76], [77]. In addition, the relative activity of each of these two functions varies greatly 
between individual members of the EAAT family [82], [83].[63], [64][62], [63][53], [54] For 
example, while EAAT1, EAAT2, and EAAT3 have little chloride conductance and play an 
important role in glutamate reuptake in the cells that express them [84], [85], EAAT4 and 
EAAT5 play a significant role in presynaptic inhibition but little role in glutamate uptake [86], 
[109]. Compared to other forms of presynaptic inhibition, EAAT5-mediated inhibition has slow 
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kinetics, with a decay time constant of around 130 ms, as opposed to 34 ms for GABACR- or 2 
ms for GABAAR-mediated inhibitory currents [110], [111].  In the retina, EAAT5 is expressed in 
the axon terminals of photoreceptors and rod bipolar cells [112]. 
Wersinger et al. demonstrated that rod bipolar EAAT5 can mediate autoinhibition, since 
glutamate release from the cell of interest can evoke EAAT5-mediated currents at its own 
synaptic terminal [112]. It has also been shown that EAAT5-mediated alloinhibition is possible, 
because glutamate spillover from neighboring rod bipolars can evoke EAAT5 currents [113]. 
However, both of these studies either used nonphysiological electrical stimulation of cells or 
bath-applied antagonists of conventional inhibition. Previous work suggested that the mode of 
presynaptic inhibition onto rod bipolar cells switches from conventional inhibitors to EAAT5-
mediated inhibition as a function of the intensity of the light stimulus, and there has been 
speculation that EAAT5 inhibition mediates light adaptation in the rod pathway [111]. In 
response to light, the depolarizing response of rod bipolar cells is limited by inhibitory 
neurotransmitters [114], and exogenous blockade of GABA and glycine is known to upregulate 
glutamate release from bipolar cells [99], [115], so the degree to which auto- or alloinhibition is 
important under physiologically-relevant conditions remains unknown (Figure 2.2). Currently, 
neither the source of glutamate that activates EAAT5 in the rod bipolar cell, nor the function of 




Figure 2.2: EAAT5-mediated presynaptic inhibition is gated by glutamate and has two potential sources 
indicated by the numbered red arrows: 1) autoinhibitory glutamate released from the rod bipolar of interest onto 
itself and 2) alloinhibitory glutamate released from neighboring rod bipolar cells.                      
 
In this chapter, I investigate these questions. I first show that both forms of inhibition occur at all 
light intensities, suggesting that the mode of inhibition does not switch across light intensities in 
the manner previously described. I then show that although EAAT5 is not a significant 
contributor to alloinhibition, it is the main source of autoinhibition to rod bipolar cells. Finally, 
in-silico modeling of the rod bipolar – AII amacrine cell synapse shows that EAAT5-mediated 
autoinhibition has a substantial effect on synaptic transmission and may be important in 
maintaining rod bipolar cell signaling within the sensitive region of the synaptic activation curve. 
2.2 Materials and Methods 
2.2.1  Animal Protocols 




2.2.2  Retinal Dissection 
Mice of either sex (28 – 60 days of age; C57BL/6J strain; The Jackson Laboratory) were dark-
adapted overnight and sacrificed using carbon dioxide. The retina was isolated, and 400 µm slice 
preparations were made from the dorsal retina. All dissection procedures were performed in 
complete darkness under infrared illumination. Dissection medium (see section 2.2.5 Solutions 
and Drugs) was continuously oxygenated. Retinal preparations were stored in an oxygenated 
dark box at room temperature until experimental use. Dissections were performed from 10 to 11 
am, and recordings were always performed in the afternoon. 
2.2.3  Whole-Cell Recordings 
Whole-cell patch recordings were made from bipolar cell somata in retinal slices by viewing 
them with an upright microscope under infrared illumination. The sample chamber was curtained 
to prevent light leakage from infrared eyepieces reaching the samples. Extracellular media was 
continuously applied to the samples via a preheated perfusion system positioned near the slice 
preparation. Electrodes were made from borosilicate glass with a P97 Flaming/Brown puller 
(Sutter Instruments) and had resistances of approximately 5 MΩ. All recordings were made at 
30°C. Signal software (Cambridge Electronic Design) was used to generate electrical command 
outputs and acquire and store data. Recordings were sampled at 5 kHz and filtered at 2 kHz with 
the four-pole Bessel filter on the Axopatch 200B (Molecular Devices). Liquid junction potentials 
were corrected at the beginning of each recording. Depending on the experiment, cells were 
either voltage clamped at 0 mV, the reversal potential for nonselective cation channels, isolating 
Cl- currents, or were held at -60 mV with ECl at 0 mV. In the latter case, the mGluR6-mediated 
cation currents ran down quickly and did not contaminate the Cl- currents. 
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2.2.4  Morphological Identification 
Sulforhodamine B (0.005%) was included in the intracellular solution for all recordings to 
identify the cell type and to confirm correct placement of puff pipettes at the rod bipolar axon 
terminal. After electrophysiological recordings were finished, cells were morphologically 
identified by their axon terminal ramification morphology and location in the inner plexiform 
layer (IPL) (Figure 2.3) [116], [117]. 
 
Figure 2.3: Differential interference contrast photomicrograph of a pipette and rod bipolar cell (RBC) 
filled with fluorescent dye (Sulforhodamine B 0.005%) following whole-cell recording in a retinal slice.                      
 
2.2.5  Solutions and Drugs 
Retinal dissections were performed in HEPES-buffered extracellular Ringer’s solution 
containing (in mM): 137 NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl, 28 glucose, 10 HEPES, 4 Na-L-
lactate, 2 Na-pyruvate, 0.5 L-glutamine, adjusted to pH 7.4 by NaOH. Physiological recordings 
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were performed in bicarbonate-buffered extracellular solution containing (in mM): 125 NaCl, 2.5 
KCl, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 20 glucose, 1.25 NaH2PO4,4 Na-L-lactate, 2 Na-pyruvate, 
0.5 L-glutamine. Extracellular solutions were continuously aerated with 95% O2 and 5% CO2 
and the pH was 7.4 at 30°C. For experiments in which cells were held at 0 mV the intracellular 
solution was (in mM): 120 CsOH, 120 D-gluconic acid, 1 CaCl2, 1 MgCl2, 11 EGTA, 10 Na-
HEPES, 10 TEA-Cl, 5 ATP-Mg, 1 GTP-Na, adjusted to pH 7.2 by CsOH. For experiments in 
which cells were held at -60 mV, the intracellular solution was (in mM): 125 CsCl, 25 HEPES, 
10 TEA-Cl, 0.5 EGTA, 2.5 ATP-Mg, 2.1 GDPβS, adjusted to pH 7.2 by CsOH. 
When bath-applied, conventional inhibitory receptor antagonists were the GABAA receptor 
antagonist (–)-bicuculline methobrimide (50 µM), GABAC receptor antagonist (1,2,5,6-
Tetrahydropyridin-4-yl)methylphosphinic acid hydrate (TPMPA) (50 µM), and glycine receptor 
antagonist strychnine (1 µM). When puff-applied, the concentrations used were 250 µM 
bicuculline, 250 µM TPMPA, and 5 µM strychnine. Puff-applied glutamate was at concentration 
2.5 mM. EAATs were blocked with DL-threo-β-benzyloxyaspartic acid (TBOA) (50 µM 
extracellularly or 3 mM intracellularly). Excitatory glutamate receptors were generally not 
targeted pharmacologically, except in Figure 2.10, when AMPA and NMDA receptors were 
blocked by bath application of 6-cyano-7-nitroquinoxaline-2,3-dione disodium salt hydrate 
(CNQX, 5 µM), and D-(–)-2-amino-5-phosphonopentanoic acid (D-AP5, 50 µM), respectively. 
Puff-applied drugs were dissolved in a HEPES-buffered extracellular solution identical to the 
one used for retinal dissections, loaded into pipettes similar to those used for patch recordings, 
and were puffed onto rod bipolar cell terminals using a Picospritzer II (Parker Hannifin). Bath-
applied drugs were dissolved into the recording solution described above and aerated using the 
same source of gas and perfused into the recording chamber using the same delivery system as 
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the control solution. Drugs were given at least 4 minutes to perfuse into and be washed out of the 
chamber before the next round of recordings, and therefore experiments with bath-applied drugs 
were performed in batches; otherwise, the order of experiments was randomized. 
2.2.6  Light Stimulation 
Full-field light stimuli were generated using a 505 nm LED projected through the optical path of 
the microscope, passing through a diffusion filter to ensure even lighting over the entire field and 
a wide enough lens to illuminate the entire retinal slice. Coarse control of the light intensity was 
achieved by inserting neutral-density filters of varying strength into the optical path. Fine control 
of light intensity was achieved by varying the current through the LED. 
2.2.7  Data Analysis 
Charge transfer was measured using the area function in Signal, and difference in charge transfer 
was calculated by simple subtraction. Standard errors of the mean (SEMs) for difference in 
charge transfer were calculated by addition of root mean squares of SEMs of the underlying 
charge transfers. P-values were calculated using two-tailed t-tests. In experiments comparing the 
same conditions across multiple light intensities, corrections for multiple comparisons were 
made using the Holm–Bonferroni method. 
2.2.8  Modeling 
The rod-bipolar to AII-amacrine cell synapse was simulated in NeuronC [118]. Each cell was 
modeled as a sphere (diameter 4 µm), and each cell’s membrane was modeled as a first-order 
resistor-capacitor circuit. The rod bipolar cell explicitly included voltage-dependent calcium 
channels (L-type, non-inactivating, 8 mS/cm2) and calcium pumps (Vmax = 20 nA/cm2, Km = 20 
µM, non-electrogenic). Calcium diffused through radial shells (n = 10) to and from an internal 
core. All other gated and non-gated channels were represented by the global membrane 
17 
 
resistance of the rod bipolar cell, which was calibrated to match our experimental data (Rm = 400 
Ω-cm2). Rod bipolar cell membrane capacitance was set to calibrate the membrane time constant 
(40 ms, Cm = 100 µF/cm2). The synapse itself was simulated by a series of filters that defined the 
transfer function for vesicle release and a temporal impulse function (release rate proportional to 
[Ca], tau = 2 ms), as well as the size of the readily-releasable pool (20) and its replenishment rate 
(50 Hz). For simplicity, release was set to be noiseless, i.e. only the average rate was simulated. 
The postsynaptic currents were generated by binding of the simulated glutamate release to a 
sequential-state Markov model of a non-desensitizing AMPA receptor/channel. A current clamp 
in the rod bipolar was driven by pre-recorded data from the experiments on real rod bipolar cells, 
and a voltage-clamp in the AII (Rm = 100 MΩ-cm2, Cm = 1 µF/cm2) was set to the membrane 
resting potential (-70 mV) to record post-synaptic currents. The presynaptic [Ca2+] was plotted 
from the Ca2+ diffusion shell closest to the simulated cell membrane. 
2.3 Results 
2.3.1  The Mode of Retinal Presynaptic Inhibition Does Not Switch with Light 
Intensity. 
Light stimuli evoke inhibitory Cl- currents on rod bipolar axon terminals that are mediated by a 
combination of amacrine cell activation of GABA and glycine receptors and glutamate-driven 
activation of EAAT5 [98], [111]. I investigated the relative contribution of each of these 
pathways in response to light stimuli. Unexpectedly, however, GABAA, GABAC, and glycine 
receptor antagonists reduced inhibition only minimally in response to dim stimuli, while further 





Figure 2.4: Example RBC IPSCs. 
Inhibitory post-synaptic currents (IPSCs) evoked by a brief (200 ms) flash of light from a rod bipolar cell (RBC) 
voltage clamped at 0 mV and bath-applied inhibitory receptor antagonists are shown. RBC IPSCs evoked by a dim 
flash of light (400 photons/µm2/s) from a black background were blocked very little by a mixture of GABA and 
glycine (gly) blockers (50 µM bicuculline, 50 µM TPMPA, 1 µM strychnine). Subsequent addition of the EAAT 
antagonist TBOA (50 µM) blocked the current.                      
 
In response to bright light stimuli, bath application of GABA and glycine receptor blockers 
significantly reduced inhibition onto rod bipolar cells, but additional bath application of TBOA 
blocked the inhibitory response further (Figure 2.5). These results differ from earlier work 
suggesting that in the dark-adapted retina, low-intensity light stimuli elicit presynaptic inhibition 
onto rod bipolar cells mediated by GABA and glycine, while high-intensity light stimuli fail to 
elicit GABA- or glycine-mediated inhibition, and instead elicit EAAT5-mediated inhibition 




Figure 2.5: The mode of light-evoked inhibition to rod bipolar cells does not depend on light intensity. 
Inhibitory post-synaptic currents (IPSCs) were evoked by a brief (200 ms) flash of light from bipolar cells voltage 
clamped at 0 mV and bath-applied inhibitory receptor antagonists. Normalized inhibitory response by light intensity 
for RBCs is shown. All stimuli were presented in the context of a zero-light background. Conventional inhibitory 
receptor blockers (open circles) had minimal effect at any light intensity compared to controls (filled circles), while 
TBOA (filled triangles) caused a significant reduction in inhibition at all light intensities above 10 ph./µm2/s. (n = 43 
cells) Error bars indicate SEM. * indicates p-value < 0.05. 
 
The EAAT5-mediated current was unique to rod bipolar cells, as conventional inhibitory 
blockers eliminated all inhibition to cone bipolar cells (Figure 2.6). This validates previous work 
and is consistent with the finding that EAAT5 is found in rod but not cone bipolar cells [111], 
[112]. All of these experiments were performed in dark-adapted retinas, and the dimmest stimuli 
that elicited an inhibitory response in either rod or cone bipolar cells were below cone sensitivity, 
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suggesting that rod input can contribute inhibition onto cone pathways in response to dim stimuli 
[120], [121]. 
 
Figure 2.6: Inhibition onto cone bipolar cells is exclusively conventional. 
Inhibitory post-synaptic currents (IPSCs) are evoked by a brief (200 ms) flash of light from bipolar cells voltage 
clamped at 0 mV and bath-applied inhibitory receptor antagonists. Normalized inhibitory response by light intensity 
for cone bipolar cells is shown. All stimuli were presented in the context of a zero-light background. Conventional 
inhibitory receptor blockers alone (open circles) completely ablated the inhibitory response compared to controls 
(filled circles). (n = 4 cells) Error bars indicate SEM. * indicates p-value < 0.05. 
 
2.3.2  GABA and Glycine Mediate Alloinhibition onto Rod Bipolar Cells. 
I was surprised by the capacity of bath-applied TBOA to block inhibitory responses to such a 
significant extent in rod bipolar cells. Others have shown that when presynaptic inhibition is 
blocked at bipolar cell terminals, downstream excitatory post-synaptic currents are enhanced 
[99], [115]. I considered that the simultaneous bath-application of GABA and glycine receptor 
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blockers may have disinhibited cells throughout the network, causing abnormally high synaptic 
activity in neighboring bipolar cells, potentially leading to artificially enhanced EAAT5-
mediated inhibition via glutamate spillover. To test this possibility, I measured the light-evoked 
inhibitory response in the presence and absence of intracellular TBOA applied through the 
recording pipette [111], and in the presence or absence of a puff application of GABA and 
glycine receptor blockers on the axon terminal (Figure 2.7). 
 
Figure 2.7: Cartoon depicting intracellular and puff application of receptor antagonists. 
Diagram illustrates experimental paradigm to limit network effects of drug application. RBCs were recorded in the 
presence and absence of intracellular TBOA (3 mM) in the recording pipette, while a second puff pipette with 
conventional inhibitor antagonists (250 µM bicuculline, 250 µM TPMPA, 5 µM strychnine) was targeted at the axon 
terminal. 
 
In the presence of puff-applied GABA and glycine antagonists, rod bipolar cells demonstrated 
substantial reduction of inhibition in response to light (Figure 2.8). In fact, conventional 
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inhibitory blockers significantly reduced inhibitory input when puff-applied, regardless of the 
presence or absence of intracellular TBOA. 
 
Figure 2.8: Puff application of GABA/glycine blockers successfully blocks the light-evoked IPSC. 
A rod bipolar cell was voltage clamped at 0 mV and a 30 ms flash of light (106 ph./µm2/s) was given in the presence 
(gray) and absence (black) of a puff starting 100 ms before the onset and ending 100 ms after the offset of light. 
 
In contrast, internal application of TBOA had no significant effect on the amount of inhibition 




Figure 2.9: Results of intracellular and puff application of receptor antagonists. 
Puff application of GABA/glycine antagonists (dark bars) blocks light-evoked IPSCs compared to controls (white 
bars) while intracellular TBOA (left) has no significant effect compared to controls (right). RBCs were voltage 
clamped at 0 mV (n = 12 cells). Error bars indicate SEM. * indicates p < 0.05. 
 
To confirm that intracellular TBOA in my preparation was capable of blocking glutamate-
mediated inhibition, I tested the responses of control and TBOA-filled rod bipolars to glutamate 
puff application at the axon terminal and demonstrated that internal TBOA reduced the responses 
to puffs of glutamate (Figure 2.10). Overall, these results indicate that conventional inhibitors, 





Figure 2.10: Intracellular application of TBOA blocks the response to glutamate. 
RBCs with (grey) and without (black) intracellular TBOA were voltage clamped at -60 mV with ECl = 0 and 5 µM 
CNQX and 50 µM D-AP5 bath-applied to block AMPA and NMDA receptors, then subjected to a brief 2.5 mM 
glutamate puff. Left: two example traces. Right: charge transfer for each category. (n = 8 cells) Error bars indicate 
SEM. * indicates p < 0.05. 
 
2.3.3  EAAT5 Mediates Autoinhibition onto Rod Bipolar Cells. 
Usage of a static voltage clamp paradigm in which the cell was clamped at a fixed voltage had 
prevented the activation of voltage-gated calcium channels in the cell of interest, blocking 
excitatory output and therefore blocking any type of autoinhibition in my recordings. Thus, I 
developed a moving voltage clamp experiment in order to test the extent of EAAT5-mediated 
autoinhibition under physiologically relevant conditions. I applied to rod bipolar cells a voltage 
pulse input modeled to duplicate the excitation pattern of a rod bipolar cell in response to a light 
pulse of matching intensity and duration [114] (Figure 2.11). The initial current responses from 
such traces would necessarily include leakage currents changing in response to the shift in 
voltage, meaning that raw amplitudes would not be informative. However, by comparing 
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responses from the same cell in the presence and absence of a given extracellularly-applied 
inhibitory receptor antagonist, the difference between the two responses could measure the 
relevant level of inhibition. I also measured the alloinhibitory responses of these cells via a fixed 
voltage and stimulation with light, to better facilitate direct comparison between auto- and 
alloinhibition under comparable conditions of resting membrane potential and ECl. 
 
Figure 2.11: Voltage pulse input. 
Input was modeled to mimic the excitatory profile of an RBC in response to the light stimuli used in this chapter 
based on data in [114]. 
 
In this manner, I compared the autoinhibitory response of rod bipolar cells in the presence and 
absence of conventional inhibitory blockers and observed small but measurable levels of GABA- 




Figure 2.12: Voltage pulse example traces with and without GABA/gly blockers. 
RBCs stimulated from a baseline of -60 mV with the voltage pulse pictured in Figure 2.11 without (grey) and with 
(black) 2 s puff application of GABA/gly blockers. GABA/gly blockers elicited a small but measurable difference 
that could be attributed to autoinhibition from conventional inhibitory sources. ECl = 0 mV. 
 
Meanwhile, the difference between TBOA and TBOA-free responses demonstrated that EAAT5 




Figure 2.13: Voltage pulse example traces with and without TBOA. 
RBCs stimulated from a baseline of -60 mV with the voltage pulse pictured in Figure 2.11 without (grey) and with 
(black) extracellular application of TBOA. TBOA elicited a larger difference than conventional blockers that could 
be attributed to autoinhibition from EAAT5. ECl = 0 mV. 
 
Overall, these results allow us to make direct comparisons, painting a more complete picture of 
the extent to which each source of inhibition impacts rod bipolar cells in response to 
physiologically-relevant stimuli. They demonstrate that autoinhibition onto rod bipolar cells is 
mediated by both conventional channels and by EAAT5, but that EAAT5 is the most significant 
mediator of autoinhibition (Figure 2.14, left). At the same time, they also confirm that EAAT5 
does not play any significant role in alloinhibition, which is largely mediated by conventional 




Figure 2.14: EAAT5 is the primary mediator of autoinhibition in RBCs. 
ECl = 0 mV. Left: Summary data for autoinhibition experiments depicted in Figures 2.12 and 2.13. Data represents 
the difference in charge transfer between two comparator conditions in individual cells. GABA/glycine-mediated 
autoinhibition and EAAT5-mediated autoinhibition were significantly different from each other and were also each 
significantly different from zero. (n = 24 cells) Right: Summary data for alloinhibition experiments. RBCs were held 
at -60 mV and flashed for 100 ms at 105 ph./µm2/s. TBOA was present or absent in the intracellular media. GABA 
and glycine blockers were puff-applied. Data represent the difference in charge transfer between populations of 
cells. GABA/glycine mediated alloinhibition was significantly different from both EAAT5-mediated alloinhibition 
and from zero. EAAT5-mediated alloinhibition was not significantly different from zero. (n = 10 cells) Error bars 
indicate SEM. * indicates p < 0.05. 
 
To demonstrate that the difference between the TBOA and TBOA-free traces in my 
autoinhibition experiments was strictly attributable to glutamate release from the cell of interest, 
I performed two control experiments. In the first, I held the cell at a reduced baseline of -100 
mV, while applying a stimulus of the same amplitude, duration, and shape as before, in order to 
keep the cell below the threshold for synaptic activation (Figure 2.15). In the second, I 
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depolarized the cell to zero potential for an extended period of time, and then briefly returned the 
cell to -60 mV and applied the standard stimulus, aiming to deplete the readily-releasable vesicle 
pool prior to stimulation (Figure 2.16). 
 
Figure 2.15: EAAT5-mediated autoinhibition is dependent on synaptic activation. 
A rod bipolar cell was stimulated from a baseline of -100 mV with the voltage pulse in Figure 2.11, without (grey) 
and with (black) extracellular application of TBOA. A lack of TBOA-sensitivity confirms that the autoinhibition 




Figure 2.16: EAAT5-mediated autoinhibition is dependent on glutamate release. 
A rod bipolar cell was stimulated from a baseline of -60 mV with the voltage pulse in Figure 2.11 immediately 
following depolarization to -30 mV for 60 s. Lack of TBOA-sensitivity confirms that EAAT5-mediated 
autoinhibition is dependent on vesicle release. 
 
In both cases, the TBOA-blockable effect was completely abolished (Figure 2.17), confirming 




Figure 2.17: EAAT5-mediated autoinhibition is dependent on synaptic activation and glutamate release: Summary 
data representing the difference in charge transfer between two comparator conditions in individual cells is shown. 
No stim indicates a cell held at -60 mV without applying a voltage stimulus. “Stim,” “-100 mV baseline stim,” and 
“depolarization before stim” indicate experiments depicted in 2.13, 2.15 and 2.16, respectively. (n = 24 cells) Error 
bars indicate SEM. * indicates p < 0.05. 
 
2.3.4  EAAT5 Inhibition Modulates Signaling to AII Amacrine Cells. 
Previous work has established that rod bipolar cell synapses are biphasic, with a transient 
component that encodes increases in contrast, and a sustained component that encodes 
luminance, mediated by depletion of the readily-releasable vesicle pool [122]. To investigate the 
role of EAAT5-mediated inhibition in modulating signaling at this synapse, I compared the 
outputs of an in-silico model of the rod bipolar – AII amacrine cell synapse when given inputs 
modulated by autoinhibition as measured by the above experiments. When stimulated with 
current inputs matching the responses of real cells in the presence and absence of TBOA, a 
model rod bipolar without EAAT5-mediated inhibition exhibited a two-fold increase in the peak 
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activation of a downstream AII amacrine cell (Figure 2.18, bottom), demonstrating that EAAT5-
mediated inhibition is substantial enough to act as an important modulator of signaling at this 
synapse. More dramatically, I also found that local intracellular calcium ion concentration at the 




Figure 2.18: Outputs of in-silico model of the RBC – AII amacrine synapse. 
The virtual RBC was stimulated with an excitatory input taken from the autoinhibition results in either the absence 
or presence of TBOA (see Figure 2.13). Top: The local intracellular calcium ion concentration at the RBC pre-
synapse. In our stimulus paradigm, under normal conditions, [Ca2+] peaks at only 0.46 µM. In the absence of 
EAAT5-mediated inhibition, however, [Ca2+] peaks at 15.8 µM. Bottom: the excitatory post-synaptic current in the 
AII amacrine cell. The control trial elicited a peak excitation of 10.5 pA, while the trial without EAAT5-mediated 
inhibition peaked at 21.9 pA. 
34 
 
Since this change in [Ca2+] was accompanied by a comparatively modest increase in peak AII 
activation, I hypothesized that in the absence of EAAT5-mediated inhibition the model cell was 
operating in the saturation plateau region of the synaptic activation curve, beyond the sensitive 
range of synaptic response. To test this hypothesis, I measured the sensitivity of both models to 
small changes in input amplitude and found that the output of the control model was indeed 32-
fold more sensitive to variation in inputs than the model lacking EAAT5 mediated inhibition 
(Figure 2.19). This meant that the control cell was indeed operating along a much steeper region 
of synaptic activation relative to the TBOA cell, supporting my hypothesis. Overall, these results 
suggest that EAAT5-mediated autoinhibition onto rod bipolar cells may be important for gain 





Figure 2.19: The synaptic sensitivity of the RBC synapse with and without EAAT5. 
The inputs to each RBC were increased and decreased by 1 pA, and the resulting change in AII peak excitation was 
quantified as a ratio of input current to output current, representing the sensitivity of the synapse to encode small 
stimulus changes. The control cell was 32 times more sensitive than the TBOA cell. This suggests that EAAT5-
mediated autoinhibition keeps the RBC within the sensitive range of synaptic activation. 
 
2.4 Discussion  
This study characterizes the relative contribution of EAAT5-mediated inhibition onto rod bipolar 
cells in response to physiologically relevant stimuli. It also compares the roles of EAAT5-
mediated autoinhibition and alloinhibition. While conventional inhibitors mediate nearly all 
alloinhibition onto rod bipolar cells, EAAT5 is the primary mediator of rod bipolar 
autoinhibition and may have a substantial impact on postsynaptic excitation of the downstream 
AII amacrine cell. Overall, these findings greatly increase understanding of the function of 
EAAT5-associated chloride channels in rod bipolar cells. 
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While activation of EAAT5 by light was observed, my results do not agree with the idea of an 
inhibitory switch in which EAAT5 specifically enables inhibition in response only to bright 
stimuli and conventional inhibitory pathways mediate inhibition in response only to dim stimuli 
[111]. Unlike the previously published work, I found EAAT-mediated inhibition across a much 
broader range of light intensities. I attempted to attribute the discrepancy between the differing 
results to a number of possibilities, including the wait time between cellular break-in and 
beginning the experiment, presence or absence of glutamine in the extracellular media, delay 
between application of flashes, thickness of the slice preparations, duration of the light stimuli, 
temperature of the prep, use of dorsal vs. ventral retina, and color of the presented light, but 
attempts to replicate the previously published finding by changing any of these variables were all 
unsuccessful (data not shown). In the end, in order to completely assure myself of the validity of 
my findings, I assayed more than ten times as many cells as the matching experiment in the cited 
paper. 
I have also shown that glutamate spillover likely activates EAAT5 inhibition less than previously 
suggested. In the past, extensive EAAT-mediated spillover transmission in rod bipolar cells has 
been reported [111], [113], but I believe these findings should be viewed with caution because, 
to my knowledge, they have always depended on either excessive direct stimulation of the 
neighboring cell or network-wide blockade by conventional inhibitors, which I have here 
demonstrated leads to non-physiologic enhancement of EAAT5-mediated inhibition through 
disinhibition of bipolar cells throughout the network. Ichinose & Lukasiewicz [111] 
demonstrated that EAAT5-mediated inhibition onto rod bipolar cells is spatially limited, 
consistent with the understanding that for glutamate to be released near the rod bipolar cell 
synapse necessitates synaptic activity from either the cell in question or a neighboring one close 
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enough to lead to spillover, which would preclude any form of long-distance lateral inhibition. 
My results here are consistent with this understanding and also bring it a step further by 
demonstrating that, under physiological stimulus conditions and in the absence of any exogenous 
network blockade of GABA or glycine, EAAT5 does not play a major role in alloinhibition. 
Nonetheless, I have demonstrated an important role for EAAT5 in rod bipolar cells: 
autoinhibition. It is well-characterized that conventional autoinhibition onto rod bipolar cells is 
mediated by A17 amacrine cells, which form a reciprocal GABAergic synapse with them [123], 
[124]. Up to this point, however, study of total autoinhibition onto rod bipolar cells has been 
neglected. This is likely because inhibitory inputs are typically studied by clamping the cell of 
interest at a fixed voltage, preventing the cell’s voltage from changing and precluding glutamate 
release, which necessarily eliminates EAAT5-mediated autoinhibitory effects from study. 
However, my findings demonstrate that the overlooked EAAT5 inhibitory feedback pathway is 
actually the most prominent source of autoinhibition in a dark-adapted rod bipolar cell. 
Furthermore, my modeling data show that this inhibition is sufficient to have a substantial effect 
on signal transmission through the rod bipolar – AII synapse and may be acting to keep the rod 
bipolar cell within the sensitive part of its activation curve. 
Because autoinhibition does not include input from parallel pathways, it cannot carry spatial 
information, but rather must mediate temporal processing. In particular, I speculate that 
autoinhibition in the rod bipolar cell specifically acts as a gain modulator, allowing the cell to 
transmit sudden changes in signaling intensity, but acting as negative feedback to push the cell 
back towards an equilibrium in response to longer stimuli. In addition, complex control over this 
filtering effect could be effectively accomplished by separate mechanisms with differing 
kinetics. EAAT-mediated inhibition onto rod bipolar cells is known to have slower kinetics than 
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conventional inhibition [110], [111]. This suggests that EAAT5-mediated inhibition may be 
acting in concert with conventional A17-mediated autoinhibition to define a sophisticated 
temporal gain modulator. 
In particular, at very low light intensities, the delayed autoinhibition from EAAT5 may act to 
enhance the relatively slow single-photon signal in the rod pathway. At low light intensities 
(around 10-3 – 10-1 photons/µm2/s), the rod bipolar cell is tuned to transmit single photon signals 
from rods. Others have shown that the transient timing of the rod bipolar vesicle release function 
is the correct duration to pass a single photon signal [27], [122]. EAAT5 autoinhibition may be 
just delayed enough to allow the single-photon transient to pass, and then inhibit the rod bipolar 
cell to counter long-term baseline depolarization. Thus, by regulating the baseline slowly, 
EAAT5 autoinhibition may prevent depletion of the readily-releasable pool and maintain the 
right level to depolarization to allow single-photon signals to be transmitted. At medium 
backgrounds (around 10-1 – 102 photons/µm2/s), EAAT5 autoinhibition may instead be acting to 
allow the contrast encoding described by Oesch and Diamond [122]. At brighter backgrounds 
than that, rod bipolar cells are highly depolarized (20 – 30 mV above their dark resting level), 
and their Ca2+ channels are likely to be inactivated when depolarized that far. 
Overall, this study increases understanding of the roles of EAATs in the retina. The removal of 
glutamate from retinal synapses is primarily performed by EAAT1, also known as GLAST, on 
Müller glial cells [125]–[127]. EAAT2 and EAAT3, which can be found on retinal neurons, are 
similarly biased towards glutamate transport and exhibit very little chloride conductance but 
appear to have a much smaller role in bulk removal of glutamate from synapses [127], [128]. 
EAAT5, on the other hand, plays almost no role in glutamate transport [86], [109], but instead 
mediates autoinhibition in rod bipolar cells, and likely plays the same role in photoreceptors as 
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well. EAAT4 has a high-affinity glutamate-gated chloride activity similar to EAAT5, but is 
primarily expressed in the cerebellum [64], where it may be acting similarly to EAAT5 in the 
retina. 
Gain modulation in sensory-system neurons is important for transmitting information on 
stimulus changes despite a wide range of baseline stimulus intensities, and the glutamate-
activated inhibition of EAAT5 makes it a natural candidate for gain modulation. My data 
supports the idea that EAAT5 is playing this role at the rod bipolar synapse. 
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Chapter 3: Functional Deficits Precede 
Structural Lesions in Diabetic Retinopathy  
3.1 Background 
Diabetic retinopathy is an end-organ complication of either type 1 or type 2 diabetes mellitus 
[87]. It is commonly understood to be the result of damage to the microvasculature and neurons 
of the retina, and is a leading cause of blindness worldwide [88]. Its prevalence is increasing at 
an alarming rate, particularly in developed countries where the incidence of type II diabetes has 
been rapidly increasing, likely due to the current epidemic of obesity and overnutrition. The 
National Eye Institute projects that more than 14.6 million Americans alone will have diabetic 
retinopathy by the year 2050 [129]. It can take many years for a diabetic patient to develop 
symptoms of retinopathy, but patients can progress quite rapidly to blindness once symptoms 
appear [89]. Disease progression involves vascular endothelial growth factor (VEGF), and anti-
VEGF therapy is commonly used in diabetes care [130], [131]. However, anti-VEGF agents 
require prolonged frequent administration, are not always effective, and may have adverse 
effects [132]. Long-term VEGF antagonism in mice may induce vision loss [133]. On the other 
hand, other treatments for diabetic retinopathy are also associated with serious adverse effects 
[134]. There is a critical need for a better understanding of the basic pathogenic mechanisms of 
this disease. 
The traditional understanding of diabetic retinopathy is that diabetes causes vascular leakage and 
edema in the retina which in turn leads to neuronal damage and loss of vision. Thus, diabetic 
retinopathy is treated clinically with drugs and procedures aimed at reducing vascular leakage, 
proliferation, and edema. However, deficits in the oscillatory potential (OP) component of the 
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electroretinogram (ERG) have been observed in retinas of both patients and diabetic animal 
models [135]. Oscillatory potentials represent processing in the inner retina and have been 
attributed to amacrine cells and ganglion cells [136]. Conversely, the ERG components that 
represent photoreceptor and bipolar cell function are unchanged when inner retinal defects are 
first detected. In morphological studies, diabetic mice lose several classes of amacrine and 
ganglion cells via apoptosis [137], [138]. Apoptotic losses, however, occur months after diabetes 
onset, whereas functional defects in these neurons can be observed within weeks [135], 
suggesting that early deficits of neuronal signaling or integration may possibly precede more 
severe changes. 
In the clinic, diabetic patients are typically first seen and treated when they present with signs 
and symptoms attributable to retinal vascular pathology; electrophysiological visual testing is not 
regularly used to assess diabetic patients [95], [96]. Thus, a better understanding of the neuronal 
deficits in the early-stage diabetic retina may lead to earlier intervention and prevention of later 
vascularization, edema, and blindness. 
A number of rodent models have been developed and used for the study of diabetic retinopathy 
[139]. Genetic models will spontaneously develop diabetes; commonly used genetic models 
include the Ins2Akita mouse, a model of type 1 diabetes in which insulin deficiency results from a 
point mutation in the Insulin-2 gene, and the db/db mouse, a model of type 2 diabetes that lacks 
the leptin receptor, which leads to overfeeding, obesity, and insulin resistance [140], [141]. The 
neurotoxin streptozotocin as also widely used to induce beta cell loss and subsequent insulin 
deficiency to model type 1 diabetes in wild-type rodents [142]. Each of these approaches has 
important limitations, however. In general, single-locus genetic models such as the db/db and 
Ins2Akita mice fail to represent the true multifactorial nature of human diabetes. Rather, some 
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elements of their pathology may be unrelated to diabetes but instead to the consequences of their 
underlying genetic alteration. More specifically, the Ins2Akita mouse is generally reflective of the 
overall physiology of type 1 diabetes but Ins2Akita mice do not develop retinopathy [143], and 
leptin signaling affects the retina [144], suggesting that db/db mice are not an ideal model for 
obesity-related diabetic retinopathy. Meanwhile, streptozotocin is used as a model for type 1 
diabetes because it directly kills pancreatic β-cells and causes rapid diabetic disease, but it also 
has off-target effects including immunosuppression [145], nephrotoxicity [146], hepatotoxicity 
[147], and neurotoxicity [148]–[150]. The undesired toxic effect on neuronal tissue obviously 
confounds the interpretation of retinal changes. In addition, streptozotocin-treated mice do not 
require insulin for survival, unlike humans with type 1 diabetes. 
Another animal model is the high-fat diet obese mouse. Rodents fed a diet of 42% fat develop 
weight gain and subsequent insulin resistance and diabetes [151], which better reflects human 
obesity-related type 2 diabetes. Animals fed the high-fat diet developed hyperinsulinemia that 
peaked at 6 months of age and was less marked by 12 months (Figure 3.1). This pattern likely 
reflects initial beta-cell hypersecretion, followed by beta-cell dysfunction and loss mirroring the 
progression of human type 2 diabetes. Until recently, these mice had not been studied 




Figure 3.1: High-fat diet fed mice develop obesity and glucose intolerance. 
(Figure taken from [152].) Male C57BL/6J mice were fed standard chow or a high-fat diet providing 42% of energy 
from fat. Insulin levels from fasting serum samples were measured using an ELISA-based method at 3, 6, and 12 
months of age. Values represent mean ± SEM from at least five independent experiments in each group. ****P < 
0.0001. 
 
In human non-proliferative diabetic retinopathy, vascular signs such as intraretinal microvascular 
anomalies, venous beading, dot-blot hemorrhages, and microaneurysms are detectable by 
ophthalmoscopy. In diabetic rodents, the equivalent identifiable pathologic features are capillary 
basement membrane thickening, atrophy of small capillaries, and a loss of pericytes known 
histologically as “pericyte ghosts” [139]. When retinas were flat mounted and trypsin-digested to 
stain for microvessel skeletons, there were no differences in the mean number of atrophic 
capillaries or pericyte ghosts between high-fat diet and chow-fed mice at 6 months of age (Figure 
3.2). However, at 12 months of age high-fat diet animals showed more atrophic capillaries and 




Figure 3.2: At an advanced age, high-fat diet fed mice develop typical lesions of diabetic retinopathy. 
(Figure taken from [152].) Retinal vasculature networks were analyzed in 6- and 12-month-old animals by trypsin 
digest of isolated and fixed retinas, followed by periodic acid Schiff/hematoxylin staining. High-fat diet fed animals 
develop significantly more atrophic capillaries (left) and pericyte ghosts (right) at 12 months, but not 6 months, of 
age, compared with chow-fed controls. Shown are quantifications of vascular lesions, as assessed by a masked 
grader. Values represent mean ± SEM from 10 independent experiments in each group. **P < 0.01, ***P < 0.001 by 
ANOVA. 
 
Evans Blue dye is commonly used as a vascular permeability assay. In normal controls, Evans 
Blue dye injected into the bloodstream stays within the plasma compartment for hours, but in 
experimental diabetes, Evans Blue dye leakage is detectable in the vitreous and neural retina 
[153]. High-fat diet fed animals have more Evans Blue leakage into the aqueous compartment 




Figure 3.3: High-fat diet feeding promotes retinal vascular permeability. 
(Figure taken from [152].) Evans Blue dye (25 mg/kg) was injected intravenously into anesthetized animals and 
allowed to circulate for 180 minutes. Quantification of dye fluorescence from aqueous paracentesis samples 
demonstrates significantly greater leakage in high-fat diet fed animals compared with controls at 12 months of age 
but not at 6 months of age. Values represent mean ± SEM. *P < 0.05 by ANOVA. 
 
Here I perform electroretinography on high-fat diet mice over time to determine the sequence of 
vascular and neurologic dysfunction in diabetes induced by feeding without administration of a 
potential neurotoxin. My findings show that high-fat diet feeding produces retinopathy in which 
neurologic dysfunction precedes vascular dysfunction. 
3.2 Materials and Methods 
3.2.1  Animals 
Protocols followed the Association for Research in Vision and Ophthalmology Statement for the 
Use of Animals and were approved by Washington University in St. Louis. C57BL/6J mice were 
free of RD1 or RD8 mutations. Animals were weaned onto Purina 4043 chow (13% kcal from 
fat, 62% kcal from carbohydrate, 25% kcal from protein) or Harlan Teklad TD 88137 HFD (42% 
kcal from fat, 43% kcal from carbohydrate, and 15% kcal from protein). 
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3.2.2  Electroretinography 
A UTAS BigShot System (LKC Technologies, Inc., Gaithersburg, MD) was used. Mice (≥5 for 
each group) were dark adapted overnight. Under red light illumination, animals were 
anesthetized with ketamine (80 mg/kg total body mass) and xylazine (15 mg/kg lean body mass). 
Pupils were dilated with 1% atropine sulfate. Body temperature was maintained at 37°C with a 
heating pad. Contact lens electrodes were placed bilaterally with appropriate reference and 
ground electrodes. 
The stimulus consisted of a full-field white light flash (10 µs) in darkness or in the presence of 
dim (30.0 candela [cd]/m2) background illumination after 10 min adaptation time. The response 
was recorded over 231 ms plus 25 ms of pretrial baseline. Between 5 and 10 repeated trials were 
averaged for each luminance, with 10 repeats used for the dimmest flashes, and 5 for the 
brightest. Raw data were processed using MATLAB software (MathWorks, Natick, MA). The 
amplitude of the a-wave was measured from the average pretrial baseline to the most negative 
point of the average trace, and the b-wave amplitude was measured from that point to the highest 
positive point, after subtracting oscillatory potentials (OPs). The eye with the larger recorded b-
wave amplitude was used for each mouse. OPs were isolated using a digital Butterworth 25 Hz 
high-pass filter and quantified using root-mean-square analysis of filtered waves, normalized to 
the maximal b-wave amplitude. The log luminance of the stimulus (log [cd · s/m2]) was 
calculated based on the manufacturer's calibrations. 
3.2.2  Statistical Analysis 
Distributions of electroretinography (ERG) responses across diet groups at different light 
intensities are described by means ± SEM. Differences were compared using two-way ANOVA, 




Although the primary clinical hallmark of diabetic retinopathy is vascular disease, antecedent or 
coincident electrophysiological changes also occur in humans [94], [154]–[156]. It is less clear 
whether neural effects are involved in the etiology of diabetic retinopathy in rodents. To 
determine whether neurologic dysfunction occurs early in high-fat diet-induced diabetic 
retinopathy, I performed full-field, stimulus-evoked scotopic and photopic electroretinograms 
(ERGs) in high-fat diet fed mice and chow-fed controls. 
After dark adaption overnight, scotopic ERG was performed with full-field white stimulus given 
across increasing intensities. Thereafter, a 10-minute period of light adaptation was performed 
against a dim white background of 30-cd/m2 luminance. Photopic ERG was recorded at 
increasing stimulus intensities. Raw ERG data were then analyzed for a-wave (scotopic reading 
only) and b-wave (in both scotopic and photopic conditions) amplitudes and implicit times. The 
raw waves were processed through a digital high-pass filter to isolate early oscillatory potentials 
(OPs), as shown in Figure 3.4. 
 
Figure 3.4: ERG analysis parameters. 
ERG responses were recorded from animals in scotopic conditions after overnight dark adaptation. A high-pass filter 




As expected, maximal ERG responses to white light stimuli for both a-waves and b-waves 
declined with age (Figure 3.5). At no age did I observe a difference in amplitudes or implicit 
times in scotopic a-waves or b-waves between HFD and control groups. There were no 





Figure 3.5: High-fat diet feeding does not alter major retinal responses to light stimuli. 
ERG responses were recorded from animals in scotopic conditions after overnight dark adaptation. ERG a-wave 
amplitudes recorded at 3, 6, and 12 months of age are plotted against stimulus luminance (left), with corresponding 
b-wave amplitudes (right). Values represent the mean ± SEM from at least five animals at each age. Decline in 
amplitudes of responses are seen with increasing age. At all tested ages, no significant differences were observed 
between animals on different diets with regard to either major ERG component (ANOVA). 
 
Amplitudes of summed OPs did not differ between dietary groups at 3 or 6 months of age 
(Figures 3.6, top and 3.7, top). However, at 12 months of age, average OP amplitudes were 
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significantly reduced in HFD-fed animals compared with chow-fed controls at all stimulus 
intensities (P < 0.05) except for the dimmest (−2.4 log [cd · s/m2]) and brightest (0.89 log [cd · 
s/m2]) (Figure 3.8, top). Examples of the preferential decline in OP amplitudes in HFD-fed 
animals compared with controls, with relative preservation of a-wave and b-wave amplitudes, are 
shown in Figure 3.9. 
 
Figure 3.6: Three-month high-fat diet fed mice do not have decreased OP amplitudes. 
Visual function in high fat diet or chow-fed animals was assessed at 3 months of age by ERG under scotopic, dark-
adapted conditions. OPs were extracted from the raw ERG trace using a high-pass filter. The root mean square 
(RMS) of all OP peaks and troughs were normalized to the amplitude of the maximal b wave. RMS of OP 
amplitudes are plotted against stimulus luminance at 3 months of age (top). Values represent the mean ± SEM from 
at least five animals. Bottom: Correlation plot of normalized OP amplitude with the area under the curve (AUC) for 
the intraperitoneal glucose tolerance test (GTT) are shown for animals at 3 months of age. Each data point represents 
a unique animal. Pearson correlation analyses were performed for animals fed each diet at each tested age, with R2 




Figure 3.7: Six-month high-fat diet fed mice do not have decreased OP amplitudes. 
Visual function in high-fat diet or chow-fed animals was assessed at 6 months of age by ERG under scotopic, dark-
adapted conditions. OPs were extracted from the raw ERG trace using a high-pass filter. The root mean square 
(RMS) of all OP peaks and troughs were normalized to the amplitude of the maximal b wave. RMS of OP 
amplitudes are plotted against stimulus luminance at 6 months of age (top). Values represent the mean ± SEM from 
at least five animals. Bottom: Reductions in OP amplitudes correlate with glucose intolerance beginning at 6 months 
of age. Correlation plots of normalized OP amplitude with the area under the curve (AUC) for the intraperitoneal 
glucose tolerance test (GTT) are shown for animals at 6 months of age. Each data point represents a unique animal. 




Figure 3.8: Twelve-month high-fat diet fed mice have decreased OP amplitudes. 
Visual function in high-fat diet or chow-fed animals was assessed at 12 months of age by ERG under scotopic, dark-
adapted conditions. OPs were extracted from the raw ERG trace using a high-pass filter. The root mean square 
(RMS) of all OP peaks and troughs were normalized to the amplitude of the maximal b wave. RMS of OP 
amplitudes are plotted against stimulus luminance at 12 months of age (top). At 12 months of age, mice fed the HFD 
demonstrate significant declines in OP amplitudes relative to controls. Values represent the mean ± SEM from at 
least five animals. *P < 0.05 by ANOVA. Bottom: Reductions in OP amplitudes correlate with glucose intolerance 
beginning at 6 months of age and continuing at 12 months. Correlation plots of normalized OP amplitude with the 
area under the curve (AUC) for the intraperitoneal glucose tolerance test (GTT) are shown for animals at 12 months 
of age. Each data point represents a unique animal. Pearson correlation analyses were performed for animals fed 




Figure 3.9: Twelve-month high-fat diet mice have decreased OP amplitudes: Example traces. 
Visual function in high-fat diet or chow-fed animals was assessed by ERG under scotopic, dark-adapted conditions. 
OPs were extracted from the raw ERG trace using a high-pass filter. Representative ERG tracings from mice fed 
each of the two indicated diets are shown, with the HFD-fed mice displaying reductions in OP amplitudes compared 
with chow-fed controls. 
 
HFD feeding promotes insulin resistance, but individual mice show variable glucose tolerance 
responses. To determine whether mice with greater glucose intolerance (i.e., higher area under 
the curve values during a glucose tolerance test) also have a greater reduction in OP amplitudes, 
we correlated OP amplitudes with area under the curve of the glucose tolerance test for 
individual mice at different ages. At 3 months (Figure 3.6, bottom), no correlation was found 
between glucose tolerance and OP amplitudes in either dietary group. However, at 6 months 
(Figure 3.7, bottom), the area under the curve of the glucose tolerance test was correlated with 
lower OP amplitudes in the high-fat diet group (Pearson R2 = 0.60, P = 0.04). In contrast, no 
such correlation was found for chow-fed animals of the same age (R2 = 0.02, P = 0.81). At 12 
months (Figure 3.8, bottom), the correlation between glucose tolerance and lower OP amplitudes 
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was also present in high-fat diet animals (Pearson R2 = 0.51, P = 0.009) but not in chow-fed 
controls (R2 = 0.12, P = 0.5). 
Prompted by this correlation, I determined whether OP kinetics may be affected in the high-fat 
diet-induced diabetes model by measuring the latency time for each of the first four OPs 
recorded on scotopic ERG at 3, 6, and 12 months (Figure 3.10). Beginning at 6 months of age, a 
significant delay in implicit time for the first two OPs (OP1 and OP2) elicited by a −0.60 log (cd 
· s/m2) white light flash was observed in HFD-fed animals (27.1 ± 2.2 ms) compared with 
controls (24.3 ± 1.8) at OP1 (P < 0.05). This delay persisted through 12 months, with an average 
OP1 implicit time of 25.6 ± 2.0 ms in high-fat diet fed animals compared with 24.2 ± 1.4 ms in 
chow-fed controls (P < 0.05) and an average OP2 implicit time of 32.0 ± 2.6 ms in high-fat diet 
fed animals compared with 30.5 ± 1.9 ms in chow-fed controls (P < 0.05). These data are 
consistent with the notion that diet-induced insulin resistance promotes early neurologic deficits 
in the retina. By ERG analysis, these deficits are manifested as reductions in amplitude and 
delays in OP responses to white light stimuli under scotopic conditions. Thus, electrophysiologic 
abnormalities detected at 6 months precede the development of vascular abnormalities at 12 
months (Figures 3.2 and 3.3) in a diabetes model induced by a clinically relevant diet without 




Figure 3.10: Delays in OP implicit times are seen in high-fat diet animals before development of vascular lesions. 
Implicit times of the first four OPs (OP1–4) were measured from ERGs generated by a 0.25 cd · s/m2 white light 
stimulus. Recordings were performed at each indicated age. At 6 months of age, HFD-fed mice show significant 
delays in the implicit times of the first two OP peaks compared with chow-fed mice. This difference persists through 
12 months of age. Shown are mean values ± SEM for each of the four measured peaks, with individual values for 






Neurologic activity in the retina is metabolically demanding [157], and it is not surprising that 
retinal neural function might be altered in diabetes. Nevertheless, diabetic retinopathy is 
considered first and foremost a disease of blood vessels. In humans and mice, the earliest visible 
signs of the disease are generally believed to be vascular. Because of this, it has largely been 
assumed that early neural insults are resultant from vascular damage in the retina. However, in 
this chapter, I demonstrate in an animal model that in diet-induced diabetes retinal function is 
disturbed before the development of detectable defects in the retinal vasculature. 
Using a clinically relevant diet, it has been shown that the development of obesity, glucose 
intolerance, and insulin resistance in mice is associated with pericyte damage and microvascular 
atrophy by 1 year of age [152]. Using ERG, I show that a functional neurologic deficit occurs by 
6 months, before vascular injury. This functional abnormality is correlated with glucose 
intolerance and persists to 12 months. 
This work is novel because the relationship between early ERG dysfunction and retinopathy 
development is confounded in other mouse models. In the streptozotocin diabetes model, ERG 
and structural vascular abnormalities have both been identified [158]–[160], but streptozotocin 
causes off-target neurologic effects [149], [150]. Streptozotocin also causes rapid onset of severe 
disease that obscures any potential early neural contribution. In the db/db mouse, which develops 
a disease more similar to type 2 diabetes due to leptin receptor deficiency, massive reductions in 
b-wave amplitude have been recorded at around 6 months of age [161], but these findings 
coincide with vascular defects, including morphological abnormalities and abnormal leakage. 
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Leptin signaling also has trophic and angiogenic effects in the retina that could have accounted 
for the ERG deficits seen in these mice [144]. Diet-induced metabolic disease in rodents has 
been shown to produce retinal inflammation and degeneration [162], [163], and a rat model of 
type 2 diabetes manifests features of retinal inflammation and vascular disease coincident with 
severe metabolic derangements [164], but these studies did not report ERG responses. 
The high-fat diet model is a slow-onset disease, accurately representing the pathophysiology of 
human type 2 diabetes complications such as retinopathy. Even after 1 year, high-fat diet mice 
do not lose inner retinal thickness [152], confirming that disease in these animals is mild and 
similar to the early stages of human retinopathy [165], [166]. My findings that OP disturbances 
precede the appearance of vascular disease are consistent with data from humans, where 
electrophysiology is altered prior to visible microvascular disease, frequently involving the same 
specific waveforms [155], [167]. 
The ERG changes shown here are small but extremely specific to OPs. Unlike the large ERG 
effects caused by mutations in visual cycle proteins, ERG changes in diabetes are expected to be 
modest. Full-field ERG represents a summed response of the neural retina to light. However, just 
like in human diabetic retinopathy, I would not expect experimentally induced rodent retinopathy 
to be uniform. In humans, multifocal ERG identifies preferentially affected regions that later 
develop classic vascular lesions of retinopathy [93], [168], but unfortunately multifocal 
recording was not possible in rodents as of the time this work was performed. Compared to 
visual function assays, structural and functional assays of blood vessel integrity offer more 
specificity due to greater spatial resolution. Given the relatively lower resolution for full-field 
ERG in mice, it is therefore meaningful that functional deficits correlated with glucose 
intolerance precede the detection of vascular defects, since I would surmise that a detection bias 
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would likely work in favor of histology, not ERG. It is also known that OP characteristics can 
lead to artifacts in b-wave recordings [169], [170], but I did not detect b-wave changes between 
groups, so this potential confounder is not an issue here. 
Distorted OPs are believed to represent perturbations of the inner retina, specifically 
dysfunctional amacrine, bipolar, and retinal ganglion cells [171], [172]. Thus, my findings 
suggest that inner retinal networks may be important early targets of diabetic disease. 
It is of course possible that early ERG dysfunction in humans and mice could be caused by 
microvascular disease that cannot be detected with current technologies. Alternatively, diet-
induced diabetes may disturb neuroglial-vascular coupling. Neurovascular coupling is mediated 
by VEGF, semaphorin 3a, nitric oxide, and arachidonic acid metabolites, all of which are known 
to be affected by diabetes [173]–[176]. Nevertheless, my findings in this chapter are only 
correlative. Additional studies are required to demonstrate how high-fat diet-induced diabetes 
affects interactions between neurons and vasculature. I believe the high-fat diet mouse model 
will continue to be useful for studying the interactions between early neuronal, glial, and 
neurovascular changes in diabetic retinopathy. Doing so will be important, because finding new 
targets or biomarkers in the high-fat diet model may accelerate the improvement of clinical 
interventions for this debilitating disease. 
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Chapter 4: Summary and Future Directions  
4.1 EAAT5 
In Chapter 2, I demonstrated the relative contribution of EAAT5-mediated inhibition onto rod 
bipolar cells in response to physiologically relevant stimuli in retinal slice explants. In this 
setting, I also compared the roles of autoinhibition, in which excitation of the cell leads to 
inhibition onto itself, and alloinhibition, which is driven by other bipolar cells. Contrary to prior 
reports, I found that EAAT5-mediated inhibition can be elicited by dim light stimuli. I also found 
that while conventional inhibitors mediate nearly all alloinhibition onto rod bipolar cells, EAAT5 
is the primary mediator of rod bipolar autoinhibition. Finally, in silico modeling demonstrated 
that EAAT5-mediated autoinhibition may have a substantial impact on postsynaptic excitation of 
the downstream AII amacrine cell. 
I speculated that autoinhibition in the rod bipolar cell may specifically act as a gain modulator, 
allowing the cell to transmit sudden changes in signaling intensity, but acting as negative 
feedback to push the cell back towards an equilibrium in response to longer stimuli. In particular, 
I hypothesized that EAAT-mediated inhibition onto rod bipolar cells may have the correct 
kinetics to enhance the relatively slow single-photon signal in the rod pathway at very low light 
intensities. While my data fit this hypothesis, it still requires experimental validation, and further 
work to investigate this question is warranted. Future experiments should present retinas with 
extremely dim stimuli in the presence and absence of EAAT5-mediated inhibition. If the 
hypothesis is correct, single-photon stimuli should cause a longer period of depolarization in the 
absence of EAAT5, such that the threshold for detection of an initial single-photon stimulus is 
60 
 
unchanged, but the downstream AII amacrine cell is better able to resolve sequential single-
photon excitations with EAAT5-mediated inhibition at the rod bipolar cell intact. 
Of course, this also raises the question of how the EAAT5 system responds to light adaptation 
more generally. While my work here did investigate responses to varying intensities of light, the 
stimuli presented here were in the context of a pure black background, on completely dark-
adapted preparations. I have done some experiments (not shown) with light-adapted 
preparations, but these were grossly light-adapted into the low photopic range, where rod bipolar 
cells will be highly depolarized even at baseline and their Ca2+ channels will be largely 
inactivated, eliminating autoinhibition. I have not done any experiments in which rod bipolar 
cells were more subtly light-adapted, to around 0.1 photons/µm2/s, for example. Repeating under 
such conditions the kind of experiments I have performed here would be quite informative in 
investigating the role that EAAT5 may play in light adaptation. 
All of these studies, and more, would also be greatly facilitated by the development of a bipolar-
cell specific genetic knockout of EAAT5. During the time I have done the work presented here, 
the only available EAAT5 mutants were constitutive knockouts, and since EAAT5 is also present 
in photoreceptors, such mice were not useful for light-stimulus experiments. However, genetic 
technologies have progressed to the point where it should now be fairly straightforward to 
generate an EAAT5 selective knockout driven by a bipolar cell specific promoter. Such a model 
would provide a valuable check on my conclusions here, and also a valuable tool for further 
experiments. A genetic paradigm would also allow for more global assays of the effects of 
EAAT5, including experiments to assess the role of EAAT5-mediated inhibition on visual 
parameters like visual sensitivity and contrast sensitivity, which can be assessed using 
optokinetic reflex or water maze behavioral testing or ganglion cell recording experiments. 
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Finally, while the findings of this work have elucidated the function of EAAT5 in the inner 
retina specifically, it is likely that it may have general implications for other neurotransmitter 
transporters that can act as ion channels elsewhere. In particular, the closely-related EAAT4 is 
already known to have a glutamate-gated chloride conductance similar to that of EAAT5 and is 
also known to be found in neuronal axon terminals – in this case in cerebellar Purkinje cells. 
Future studies should investigate whether EAAT4 is playing the same functional role in the 
cerebellum that EAAT5 is in the inner retina. 
4.2 Diabetic Retinopathy 
In Chapter 3, I characterized the course of electroretinographic dysfunction in a high-fat diet–
induced model of diabetes in mice. Mice weaned to chow or to a high-fat diet were tested for 
electroretinographic dysfunction at 3, 6 and 12 months of age. There was no evidence of 
microvascular disease in these mice until 12 months. However, at as early as 6 months, high fat 
fed mice demonstrated increased latencies and reduced amplitudes of oscillatory potentials (a 
marker reflective of inner retinal neurons) when compared with controls. These 
electroretinographic abnormalities were correlated with glucose intolerance. 
The results suggest that disease in the diabetic milieu may progress through neuronal stages in 
the inner retina long before the development of vascular lesions representing the classic hallmark 
of diabetic retinopathy. However, the neuronal types and the cellular and synaptic processes 
involved in the functional deficits are unknown. Identifying these components could possibly 
lead to novel interventions to treat eye disease. 
When action potentials in the retina are blocked with tetrodotoxin, oscillatory potentials are 
reduced [177], [178]. This suggests that oscillatory potentials represent the contributions of 
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spiking neurons, meaning amacrine cells, ganglion cells, or both. Thus, action potentials may be 
compromised in amacrine or ganglion cells in the early stages of diabetic retinopathy. To 
determine whether this is the case, and, if so, which cells, future work should compare spiking 
activity in ganglion cells and spiking amacrine cells in high-fat diet and control mice. This 
should be feasible to do via single-cell patch-clamp recordings like those used here in Chapter 2. 
If changes in innate spiking ability are observed, it should then be possible to further isolate the 
specific molecular changes involved by comparing the activation and inactivation properties of 
pharmacologically-isolated sodium and potassium channels in these cells. 
Alternatively, it may be that altered inputs to amacrine or ganglion cells are responsible for the 
changes in ERGs I have observed here. For example, reduced excitatory input or increased 
inhibitory input to ganglion cells may lead to the reduced oscillatory potentials seen here. Future 
work should also investigate this possibility, by comparing the light-evoked excitatory or 
inhibitory post-synaptic currents onto ganglion cells from high-fat diet and control mice. From 
there, changes can be further narrowed down to changes in neurotransmitter release versus 
changes in receptor responsiveness by comparing the effects of paired pulse protocols versus the 
effects of spontaneous postsynaptic current recordings. 
Of course, the question of whether or not the early electrical changes observed in these mice 
actually precede or coincide with changes in visual function also remains. In humans, data has 
demonstrated that changes in the ERG oscillatory potential precede measurable visual loss [90]–
[94]. If this is the case, the high-fat diet model would be most clinically useful if it also 
recapitulates this aspect of disease. Future work should assess the visual function of high-fat diet 
mice versus controls using visual parameters like contrast detection, spatial resolution, temporal 
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resolution, and light adaptation, which can all potentially be assessed using optokinetic reflex or 
water maze behavioral testing. 
Finally, future work should investigate the possibility that electroretinographic testing could 
become more routinely used to screen for retinopathy in diabetic patients. First in patients, and 
now in mice, it has been shown that the oscillatory potential is a very early marker of disease 
progression that precedes the development of vascular changes in the retina. Clinically, however, 
routine screening is almost exclusively funduscopic, meaning that patients are not detected as 
having retinopathy until vascular changes have already begun. Perhaps because oscillatory 
potentials are a relatively obscure parameter compared to a-waves and b-waves, and because 
current treatments are geared toward halting vascular progression anyway, electroretinographic 
screening is not typically used. Indeed, it may not yet be practical to screen patients with ERGs 
in the general diabetic population, but researchers studying retinopathy therapeutics may benefit 
from ERG testing to identify the development of retinopathy in clinical study populations, which 
could, in itself, lead to the development of therapeutics that can be used in the earliest stages to 
prevent retinopathy progression. Thus, there is the potential for great clinical benefit if these 
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